mesowatch
HomeJury Awards $17M in Compensation for Asbestos-Related Disease Against Georgia-Pacific
divider

Jury Awards $17M in Compensation for Asbestos-Related Disease Against Georgia-Pacific

jury verdict award

A jury in the 11th Judicial Circuit of Florida handed down a hefty $17 million in compensation for asbestos-related disease after a trial against construction products distributor and manufacturer Georgia-Pacific. The plaintiff was a former painting supervisor named Roy Taylor who worked on a project in Saudi Arabia in the late ‘70s. While there, he was responsible for sanding down wall surfaces to prepare for painting.

Much of the sanding work required going over a Georgia-Pacific joint compound product, which was known by the company to contain significant amounts of asbestos. The subsequent white dust would cover Taylor’s uniform, creating a vector for long-term exposure to the asbestos chemicals.

Taylor was diagnosed with asbestos-related cancer some 40 years later. During trial, his physician testified that Taylor had as little as a year to live because of the aggressive nature of his disease.

The total jury award included $13 million in compensation for asbestos-related disease to Taylor as well as $4 million to his wife Suzanne as damages for emotional suffering and future loss of companionship.

Two Defendants Become One in Battle of Compensation for Asbestos-Related Disease

Initially in the trial, Union Carbide — the manufacturer of the asbestos derivatives Georgia-Pacific used in its product — was considered a co-defendant. However, the jury cleared Union Carbide of all liability, likely during deliberations.

Taylor’s head attorney was unsurprised at Union Carbide’s clearing from potential liability. “If [Georgia-Pacific] didn’t buy it from Union Carbide, they would have bought it from someone else,” he asserted.

A sense that Georgia-Pacific had willingly and maliciously exposed Taylor to the dangers of the product during his duties permeated the plaintiff’s central argument. The attorney even displayed a 1974 brochure from Georgia-Pacific, advertising the amount of asbestos used in their joint compound product.

Union Carbide declined to comment to the Courtroom View Network (CVN) reporter covering the trial. Georgia-Pacific spokeswoman Karen Cole released a statement to the media outlet saying that while they sympathize with the suffering the Taylor family endured, the verdict against them was highly disappointing. “We believe the evidence in the trial established that Mr. Taylor was not exposed to Georgia-Pacific’s product and that our product did not play a role in his disease,” she said.

However, the plaintiff’s attorney was not buying this argument. “I think there was overwhelming evidence of the exposure in Saudi Arabia,” he said, denying the defense’s conjecture that Taylor could have been exposed by any number of products after his Saudi Arabia project had completed.

Predicted Low Risk of Appeal

While CVN reports that a sizable portion of trials resulting in compensation for asbestos-related disease usually end in a subsequent appeal, the plaintiff’s attorney felt that this would not be the case. Both sides presented their arguments “pretty much by the book,” he said, concluding that they “don’t really have much to appeal.”

While Mr. Taylor’s condition is not predicted to recover, the compensation for asbestos-related disease can help pay back the expense of medical treatment along with damages for the pain and suffering he and his wife have endured.

If you suspect that you have been exposed to asbestos or you have been diagnosed with an asbestos-related disease, acting fast is the only way to increase your chances of receiving compensation for asbestos exposure. Use the button below to find a lawyer immediately and get your case started.

Matthew Davis

Reading Time: 1 mins

Published On: July 7, 2016

Matthew Davis - author

Matthew Davis is a freelance journalist who has covered civil litigation for a variety of publications. He joined Mesowatch in 2016 and covers asbestos litigation developments in the U.S., as well as newsworthy asbestos cases.

More to Read

Section Divider

Amna Anees - November 17, 2024

CHMP Recommends Pembrolizumab and Chemo for Pleural Mesothelioma

Mini Divider
Mesowatch Logo

Mesowatch serves as an industry watchdog and advocates for patients and families affected by asbestos by providing reliable and up-to-date news stories and information on asbestos and mesothelioma.

NAVIGATE

About UsEditorial GuidelinesNewsSupport and ResourcesPrivacy PolicySitemap

CONTACT US

Email: support@mesowatch.com

Phone: (866) 402-1000

Address: 3260 N Hayden Rd, Suite 210, Scottsdale, AZ 85251

Copyright © 2024 by Mesowatch. All Rights Reserved.
At Mesowatch, we strive to provide helpful information for your journey. Please remember that the content on our website is for informational purposes only and is protected by copyright law. It is not a substitute for professional medical or legal advice. We encourage you to consult qualified professionals for any health or legal concerns. Disclaimer